Reduced fibrinolytic potential in patients with arterial occlusive disease (AOD) in comparison with normal subjects.
When combining angioplasty and local lysis with urokinase (UK) in treatment of peripheral arterial occlusions we have observed marked differences in the individual patient's response irrespective of the age of the thrombus. The extensive arteriosclerotic changes revealed by angiography in some of these patients suggest a reduced fibrinolytic potential depending on the underlying disease. In the standard in vitro test system we measured the UK-dependent thrombolysis in blood samples from 10 normal controls at UK concentrations of 150, 200, and 300 IU/ml of whole blood. In comparison we determined the whole blood thrombolysis time (WBTT) of 10 patients with AOD using UK concentrations of 150, 200, and 300 IU/ml of whole blood. The mean WBTT values for normal controls obtained at UK concentrations of 150 IU/ml, 200 IU/ml, and 300 IU/ml, respectively, amounted to 9.5, 5.5, and 3.5 minutes, respectively, while in patients mean values of 20.7, 8.1, and 5.5 minutes, respectively, were found. Studies on plasma samples had shown that the lysis time could be shortened in a dose-dependent manner by addition of lys-plasminogen (LYS-PLASMINOGEN Steam Treated) and to some extent also glu-plasminogen. Since lys-plasminogen gave clearly superior results we tried to improve the lytic potential in terms of a shortening of the WBTT by adding different doses of lys-plasminogen (0.14-0.56 CU/ml whole blood) to each patient sample. Although the individual response varied, the addition of lys-plasminogen to the patient samples resulted in a clear dose-dependent improvement of pathologically prolonged lysis times.(ABSTRACT TRUNCATED AT 250 WORDS)
Hartl
D
D
Allgemeine Poliklinik, Wien, Austria.
Tiso
E
E
Anderle
K
K
Philapitsch
A
A
Anger
G
G
D000990:Antithrombin III / Q000032:analysis; D001157:Arterial Occlusive Diseases / Q000097:blood* / Q000150:complications; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000209:etiology; D001780:Blood Coagulation Tests; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology; D010958:Plasminogen / Q000032:analysis / Q000494:pharmacology; D012016:Reference Values
D010446:Peptide Fragments; C018998:lysyl-plasminogen; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen